References
- Peters JM, Van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondyloarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004; 34: 585–592
- Divecha H, Sattar N, Rumley A, Cherry L, Lowe GDO, Sturrock R. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: Relevance of systemic inflammation. Clin Sci 2005; 109: 171–176
- Caliskan M, Erdogan D, Gullu H, Yilmaz S, Gursoy Y, Yildirir A, Yucel E, Muderrisoglu H. Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 2008; 196: 306–312
- Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost 2003; 1: 1897–1905
- Toplak H, Wascher TC. Cardiovascular risk factors in obesity. Influence of weight reduction on platelet volume: Different effects of hypocaloric diet and a very low calorie diet. Eur J Clin Invest 1994; 24: 778–780
- Yazici M, Kaya A, Kaya Y, Albayrak S, Cinemre H, Ozhan H. Lifestyle modification decreases the mean platelet volume in prehypertensive patients. Platelets 2009; 20: 58–63
- Bath PM, Butterworth RJ. Platelet size: Measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7: 157–161
- Hekimsoy Z, Payzin B, Ornek T, Kandogan G. Mean platelet volume in Type 2 diabetic patients. J Diabetes Complications 2004; 18: 173–176
- Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA, Kiraz S, Ertenli I, Calguneri M. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine 2008; 75: 291–294
- Romero-Sánchez C, Robinson WH, Tomooka BH, Londoño J, Valle-Oñate R, Huang F, Deng X, Zhang L, Yang C, Yan Yu DT. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol 2008; 27: 1429–1435
- Wang F, Yan C, Xiang H, Xing T, Wang N. The significance of platelet activation in ankylosing spondylitis. Clin Rheumatol 2008; 27: 767–769
- Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–368
- Spoorenberg A, Van Der Heijde D, De Klerk E, Dougados M, De Vlam K, Mielants H, van der Tempel H, van der Linden S. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999; 26: 980–984
- Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D, Braun J. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008; 67: 511–517
- Van den Bosch F, Kruithof E, Baeten D, Herssens A, De Keyser F, Mielants H, Veys EM. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002; 46: 755–765
- Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: A literature review. J Rheumatol 1999; 26: 966–970
- Haubelt H, Simon M, Anders Ch, Hellstern P. Platelet function tests for monitoring of acetylsalicylic acid: Clinical significance in antiplatelet treatment. Hamostaseologie 2004; 24: 196–202